Analytical Data
-
Gene name
PTGIS
- Application
-
Alternative Names
PTGIS；CYP8；CYP8A1；Prostacyclin synthase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16647
-
Expression Region
1-500aa
-
AA Sequence
MAWAALLGLLAALLLLLLLSRRRTRRPGEPPLDLGSIPWLGYALDFGKDAASFLTRMKEKHGDIFTILVGGRYVTVLLDPHSYDAVVWEPRTRLDFHAYAIFLMERIFDVQLPHYSPSDEKARMKLTLLHRELQALTEAMYTNLHAVLLGDATEAGSGWHEMGLLDFSYSFLLRAGYLTLYGIEALPRTHESQAQDRVHSADVFHTFRQLDRLLPKLARGSLSVGDKDHMCSVKSRLWKLLSPARLARRAHRSKWLESYLLHLEEMGVSEEMQARALVLQLWATQGNMGPAAFWLLLFLLKNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITREVVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPEVFKYNRFLNPDGSEKKDFYKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINADVEIPEFDLSRYGFGLMQPEHDVPVRYRIRP
-
Molecular Weight
57.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGIS, or Prostaglandin I2 Synthase, is an important enzyme involved in the synthesis of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. Its role in the cardiovascular system and its involvement in various pathological conditions, such as hypertension, atherosclerosis, and thrombosis, make PTGIS a key target for therapeutic intervention. Research into PTGIS has expanded significantly due to its potential implications in cardiovascular health and disease. The recombinant expression of PTGIS has allowed for the detailed study of its structure and function, facilitating insights into enzymatic mechanisms and the regulation of prostacyclin production. Understanding PTGIS at a molecular level also paves the way for the development of novel drugs aimed at modulating its activity, potentially leading to new treatments for cardiovascular diseases. Additionally, the exploration of PTGIS's role in cellular signaling pathways and its interaction with other biomolecules contributes to a broader understanding of its physiological relevance and therapeutic potential. As researchers continue to investigate PTGIS and its recombinant forms, the findings may ultimately lead to enhanced strategies for the prevention and management of cardiovascular-related disorders.
